Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Bleeding
- Breakthrough Bleeding
- Implants
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Triple (Participant, Investigator, Outcomes Assessor)Masking Description: Placebo-controlled Computer-generated randomization schemaPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 15 years and 45 years
- Gender
- Only males
Description
The investigators are proposing a randomized, double blind placebo-controlled clinical trial over a 30-day reference period for treatment of women experiencing bothersome bleeding while using the etonogestrel (ENG) contraceptive implant. The primary outcome of the study will be the total number of a...
The investigators are proposing a randomized, double blind placebo-controlled clinical trial over a 30-day reference period for treatment of women experiencing bothersome bleeding while using the etonogestrel (ENG) contraceptive implant. The primary outcome of the study will be the total number of amenorrhea days in a 30-day reference period. The study has a number of secondary outcomes (see study objectives) focused around the efficacy of oral curcumin to stop bleeding/spotting and for how long.
Tracking Information
- NCT #
- NCT04205929
- Collaborators
- Merck Sharp & Dohme Corp.
- Investigators
- Not Provided
Get Well Soon